PTC Therapeutics (PTCT) Director Michael Schmertzler Sells 25,000 Shares

What Happened Michael Schmertzler, a director of PTC Therapeutics (PTCT), disposed of 25,000 shares in four open-market sales on August 26–27, 2026 for total proceeds of $1,806,510. The individual transactions reported were:

• Aug 26: 6,874 shares at $72.74 — $500,015
• Aug 26: 5,626 shares at $73.18 — $411,711
• Aug 27: 11,890 shares at $71.55 — $850,730
• Aug 27: 610 shares at $72.22 — $44,054
  All transactions are sales (code S).

Key Details

• Dates and prices: Aug 26–27, 2026; reported per-share weighted/average prices and price ranges in the filing (see footnotes).
  • Weighted-range notes: trades executed across price ranges roughly $70.94–$73.40 (see filing footnotes F2, F4–F6 for exact ranges).
• Total shares sold: 25,000 for total proceeds of $1,806,510.
• Shares owned after transaction: not specified in the excerpt of the Form 4 provided.
• Notable footnotes: sales were effected pursuant to a written Rule 10b5‑1 plan adopted by Section Six Partners, L.P. on May 14, 2026 (F1). The shares represent holdings of Section Six Partners, L.P.; Schmertzler is a general and limited partner and disclaims beneficial ownership except to the extent of his pecuniary interest (F3). Weighted-average price reporting and trade-price ranges are noted in F2, F4–F6; the filer offers to provide per-trade breakdowns on request.
• Filing timeliness: Form 4 was filed Aug 28, 2026 for trades on Aug 26–27, which is within the usual two-business-day reporting window (no late filing indicated).

Context These were open-market sales executed under a prearranged 10b5‑1 plan — a mechanism directors often use to schedule routine transactions. Sales do not necessarily indicate a change in sentiment; the 10b5‑1 plan and the involvement of Section Six Partners, L.P. are important disclosures for understanding the structure and potential prearrangement of these trades.